ArticleACS infectious diseases2019
Discovery and Mechanistic Study of a Novel Human-Stimulator-of-Interferon-Genes Agonist.
Article in ACS infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 56 citations in OpenAlex.
- The diversity of STING in regulating immune cell function and its role in liver diseases: from bench to bedside.Cell & bioscience · 2026Review
- STING agonists as antiviral agents.FEBS letters · 2026Review
- Antiviral and immune modulatory activities of STING agonists in a mouse model of persistent hepatitis B virus infection.PLoS pathogens · 2025Article
- Conjugated STING agonists.Molecular therapy. Nucleic acids · 2025Review
- Advances in antiviral strategies targeting mosquito-borne viruses: cellular, viral, and immune-related approaches.Virology journal · 2025Review
- Nanoparticle-Based Strategies to Enhance the Efficacy of STING Activators in Cancer Immunotherapy.International journal of nanomedicine · 2025Review
- Activation of the cGAS-sting Pathway Mediated by Nanocomplexes for Tumor Therapy.Current pharmaceutical design · 2025Review
- Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies.Cancer biology & medicine · 2024Review
- Mitochondrial DNA-triggered innate immune response: mechanisms and diseases.Cellular & molecular immunology · 2023Review
- Significance of the cGAS-STING Pathway in Health and Disease.International journal of molecular sciences · 2023Review
- Biomaterial-enabled therapeutic modulation of cGAS-STING signaling for enhancing antitumor immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Review
- Mn-based cGAS-STING activation for tumor therapy.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- The cGAS/STING signaling pathway: a cross-talk of infection, senescence and tumors.Cell cycle (Georgetown, Tex.) · 2023Article
- The battle between the innate immune cGAS-STING signaling pathway and human herpesvirus infection.Frontiers in immunology · 2023Review
- Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer Immunotherapy.Pharmaceutics · 2022Article
- Radioresistant cells initiate lymphocyte-dependent lung inflammation and IFNγ-dependent mortality in STING gain-of-function mice.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Nanodelivery of STING agonists against cancer and infectious diseases.Molecular aspects of medicine · 2022Review
- Post-Translational Modifications of STING: A Potential Therapeutic Target.Frontiers in immunology · 2022Review
- Advances in cGAS-STING Signaling Pathway and Diseases.Frontiers in cell and developmental biology · 2022Review
- A yellow fever virus NS4B inhibitor not only suppresses viral replication, but also enhances the virus activation of RIG-I-like receptor-mediated innate immune response.PLoS pathogens · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 2 countries.
Funding
Abstract
Stimulator of interferon genes (STING) is an integral ER-membrane protein that can be activated by 2'3'-cGAMP synthesized by cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) upon binding of double-stranded DNA. It activates interferon (IFN) and inflammatory cytokine responses to defend against infection by microorganisms. Pharmacologic activation of STING has been demonstrated to induce an antiviral state and boost antitumor immunity. We previously reported a cell-based high-throughput-screening assay that allowed for identification of small-molecule cGAS-STING-pathway agonists. We report herein a compound, 6-bromo-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.